Literature DB >> 17384213

Absence of RET gene point mutations in sporadic thyroid C-cell hyperplasia.

Enrico Saggiorato1, Ida Rapa, Francesca Garino, Gianni Bussolati, Fabio Orlandi, Mauro Papotti, Marco Volante.   

Abstract

Progression from C-cell hyperplasia (CCH) to medullary thyroid carcinoma (MTC) has been demonstrated to date only in familial forms, whereas in nonfamilial MTC, such hypothesis is suggested by the rare concurrence of both lesions, although no epidemiological and molecular data are available to prove or disprove this event. Therefore, the clinical management of patients with sporadic CCH is controversial. To evaluate the malignant potential of sporadic CCHs, pure laser-microdissected C-cell populations of 24 CCH cases, either reactive or associated with nonfamilial MTC, were analyzed for MTC-associated protein neural cell adhesion molecule expression and RET point mutations in exons 10, 11, 15, and 16, by using immunohistochemistry and polymerase chain reaction-single-strand conformation polymorphism/heteroduplex electrophoresis/direct sequencing, respectively. No RET mutations were found in any of the 24 CCH cases, whereas M918T mutation was detected in three concomitant MTCs. Neural cell adhesion molecule was immunoreactive in the majority of CCH associated with MTC even in the absence of morphological atypia, but not in reactive forms. The absence of RET alterations in all cases of CCH examined supports the hypothesis that the development of MTC is independent of pre-existing CCH in the nonfamilial setting; thus, sporadic CCH should not be considered a risk factor for nonfamilial MTC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17384213      PMCID: PMC1867441          DOI: 10.2353/jmoldx.2007.060166

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  19 in total

1.  Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects.

Authors:  Georgios Karanikas; Abbas Moameni; Christian Poetzi; Georg Zettinig; Klaus Kaserer; Christian Bieglmayer; Bruno Niederle; Robert Dudczak; Christian Pirich
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

2.  Sporadic medullary microcarcinoma of the thyroid.

Authors:  Y Mizukami; H Kurumaya; A Nonomura; T Michigishi; S Terahata; M Noguchi; T Hashimoto; F Matsubara
Journal:  Histopathology       Date:  1992-10       Impact factor: 5.087

3.  Simultaneous occurrence of medullary and follicular carcinoma in the same thyroid lobe.

Authors:  T Tanaka; N Yoshimi; N Kanai; H Mori; K Nagai; A Fujii; S Sakata; N Tokimitsu
Journal:  Hum Pathol       Date:  1989-01       Impact factor: 3.466

Review 4.  C-cell hyperplasia and medullary thyroid microcarcinoma.

Authors:  J A Albores-Saavedra; J E Krueger
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

5.  Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients.

Authors:  K Kaserer; C Scheuba; N Neuhold; A Weinhäusel; O A Haas; H Vierhapper; B Niederle
Journal:  Am J Surg Pathol       Date:  2001-10       Impact factor: 6.394

6.  Mixed medullary-follicular thyroid carcinoma. Molecular evidence for a dual origin of tumor components.

Authors:  M Volante; M Papotti; J Roth; P Saremaslani; E J Speel; R V Lloyd; J A Carney; P U Heitz; G Bussolati; P Komminoth
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

7.  Prevalence of C-cell hyperplasia in patients with normal basal and pentagastrin-stimulated calcitonin.

Authors:  C Scheuba; K Kaserer; H Kotzmann; C Bieglmayer; B Niederle; H Vierhapper
Journal:  Thyroid       Date:  2000-05       Impact factor: 6.568

8.  Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2.

Authors:  L M Mulligan; E Gardner; B A Smith; C G Mathew; B A Ponder
Journal:  Genes Chromosomes Cancer       Date:  1993-03       Impact factor: 5.006

9.  Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia.

Authors:  Jorge Lima; José Teixeira-Gomes; Paula Soares; Valdemar Máximo; Mrinalini Honavar; Dillwyn Williams; Manuel Sobrinho-Simões
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

10.  C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients.

Authors:  Serge Guyétant; Nicolas Josselin; Fréderique Savagner; Vincent Rohmer; Sophie Michalak; Jean-Paul Saint-André
Journal:  Mod Pathol       Date:  2003-08       Impact factor: 7.842

View more
  6 in total

1.  Revisiting the Significance of Prominent C Cells in the Thyroid.

Authors:  Talia L Fuchs; Stephen E Bell; A Chou; Anthony J Gill
Journal:  Endocr Pathol       Date:  2019-06       Impact factor: 3.943

Review 2.  [Thyroid C cells and their pathology: Part 1: normal C cells, - C cell hyperplasia, - precursor of familial medullary thyroid carcinoma].

Authors:  S Ting; S Synoracki; K W Schmid
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

3.  [Multiple endocrine neoplasia type 2].

Authors:  S-Y Sheu; K W Schmid
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

Review 4.  [Molecular pathology of thyroid tumors].

Authors:  K W Schmid
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

5.  Tenascin C in medullary thyroid microcarcinoma and C-cell hyperplasia.

Authors:  Oskar Koperek; Astrid Prinz; Christian Scheuba; Bruno Niederle; Klaus Kaserer
Journal:  Virchows Arch       Date:  2009-05-30       Impact factor: 4.064

6.  Predominant RET Germline Mutations in Exons 10, 11, and 16 in Iranian Patients with Hereditary Medullary Thyroid Carcinoma.

Authors:  Mehdi Hedayati; Marjan Zarif Yeganeh; Sara Sheikhol Eslami; Shekoofe Rezghi Barez; Laleh Hoghooghi Rad; Fereidoun Azizi
Journal:  J Thyroid Res       Date:  2011-06-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.